Human papillomavirus E6/E7 mRNA testing as a predictive marker for cervical carcinoma

Expert Review of Molecular Diagnostics

Volumn 8, Issue 4, 2008, Pages 405-415

  Lie, A Kathrine ^a   Kristensen, Gunnar ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

Cervical carcinoma; HPV E6 E7 mRNA; Predictive marker

Indexed keywords

BIOLOGICAL MARKER; MESSENGER RNA;

CANCER GRADING; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; DIAGNOSTIC TEST; DNA DETERMINATION; GENE AMPLIFICATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 6; IN SITU HYBRIDIZATION; PAPILLOMA VIRUS; PROTEIN ANALYSIS; REVIEW; SCREENING TEST; UTERINE CERVIX CARCINOMA; VIRUS DETECTION; VIRUS STRAIN; WART VIRUS 7;

DNA, NEOPLASM; DNA, VIRAL; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS E7 PROTEINS; PAPILLOMAVIRUS INFECTIONS; RNA, MESSENGER; RNA, NEOPLASM; RNA, VIRAL; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 46949095918     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.4.405     Document Type: Review

References (65)

1. Parkin DM, Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 24(Suppl. 3), S11-S25 (2006).
2. Munoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 24(Suppl. 3), S1-S10 (2006).
3. Walboomers JMM, Jacobs MV, Manos MM et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19 (1999).
4. IARC Monograph Working group. Human papillomaviruses. IARC Press, Lyon, France (2007).
5. Bosch FX, de Sanjose S. Chapter 1: human papillomavirus and cervical cancer-burden and assessment of causality. J. Natl Cancer Inst. Monogr. 31, 3-13 (2003).
6. De Villiers EM, Fauquet C, Broker TR, Bernard HU, zur Hausen H. Classification of papillomaviruses. Virology 324(1), 17-27 (2004).
7. Munoz N, Bosch FX, de Sanjose S et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N. Engl. J. Med. 348(6), 518-527(2003).
8. Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat. Rev. Cancer 2(5), 342-350 (2002).
9. Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 24(Suppl. 3), S42-S51 (2006).
10. Woodman CB, Collins SI, Young LS. The natural history of cervical HPV infection: unresolved issues. Nat. Rev. Cancer 7(1), 11-22(2007).
11. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin. Sci. (Lond.) 110(5), 525-541 (2006).
12. Gage JR, Meyers C, Wettstein FO. The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. J. Virol. 64(2), 723-730 (1990).
13. Werness BA, Levine AJ, Howley PM. Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science 248(4951), 76-79 (1990).
14. Brink AA, Snijders PJ, Meijer CJ. HPV detection methods. Dis. Markers 23(4), 273-281 (2007).
15. Evans MF, Cooper K. Human papillomavirus integration: detection by in situ hybridization and potential clinical application. J. Pathol. 202(1), 1-4 (2004).
16. Qureshi MN, Rudelli RD, Tubbs RR, Biscotti CV, Layfield LJ. Role of HPV DNA testing in predicting cervical intraepithelial lesions: comparison of HC HPV and ISH HPV. Diagn. Cytopathol. 29(3), 149-155 (2003).
17. Hesselink AT, van den Brule AJ, Brink AA et al. Comparison of hybrid capture 2 with in situ hybridization for the detection of high-risk human papillomavirus in liquid-based cervical samples. Cancer 102(1), 11-18 (2004).
18. Layfield LJ, Qureshi MN. HPV DNA testing in the triage of atypical squamous cells of undetermined significance (ASCUS): cost comparison of two methods. Diagn. Cytopathol. 33(2), 138-143 (2005).
19. Qureshi MN, Bolick D, Ringer PJ, Spagler FL, Zimmerman G. HPV testing in liquid cytology specimens: comparison of analytic sensitivty and specificity for in situ hybridization and chemiluminescent nucleic acid testing. Acta Cytol. 49(2), 120-126 (2005).
20. Arbyn M, Sasieni P, Meijer CJ, Clavel C, Koliopoulos G, Dillner J. Chapter 9: clinical applications of HPV testing: a summary of meta-analyses. Vaccine 24(Suppl. 3), S78-S89 (2006).
21. Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N. Engl. J. Med. 357(16), 1579-1588 (2007).
22. Cuzick J, Clavel C, Petry KU et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int. J. Cancer 119(5), 1095-1101 (2006).
23. Castle PE, Schiffman M, Burk RD et al. Restricted cross-reactivity of hybrid capture 2 with nononcogenic human papillomavirus types. Cancer Epidemiol. Biomarkers Prev. 11(11), 1394-1399 (2002).
24. Lie AK, Risberg B, Borge B et al. DNA-versus RNA-based methods for human papillomavirus detection in cervical neoplasia. Gynecol. Oncol. 97(3), 908-915 (2005).
25. Poljak M, Marin IJ, Seme K, Vince A. Hybrid Capture II HPV test detects at least 15 human papillomavirus genotypes not included in its current high-risk probe cocktail. J. Clin. Virol. 25(Suppl. 3), S89-S97 (2002).
26. Klaassen CH, Prinsen CF, de Valk HA, Horrevorts AM, Jeunink MA, Thunnissen FB. DNA microarray format for detection and subtyping of human papillomavirus. J. Clin. Microbiol. 42(5), 2152-2160 (2004).
27. Park TC, Kim CJ, Koh YM et al. Human papillomavirus genotyping by the DNA chip in the cervical neoplasia. DNA Cell Biol. 23(2), 119-125 (2004).
28. Schmitt M, Bravo IG, Snijders PJ, Gissmann L, Pawlita M, Waterboer T. Bead-based multiplex genotyping of human papillomaviruses. J. Clin. Microbiol. 44(2), 504-512(2006).
29. Sandri MT, Lentati P, Benini E et al. Comparison of the Digene HC2 assay and the Roche AMPLICOR human papillomavirus (HPV) test for detection of high-risk HPV genotypes in cervical samples. J. Clin. Microbiol. 44(6), 2141-2146 (2006).
30. Carozzi F, Bisanzi S, Sani C et al. Agreement between the AMPLICOR human papillomavirus test and the hybrid capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease. J. Clin. Microbiol. 45(2), 364-369 (2007).
31. Halfon P, Trepo E, Antoniotti G et al. Prospective evaluation of the hybrid capture 2 and amplicor human papillomavirus (hpv) tests for detection of 13 high-risk hpv genotypes in atypical squamous cells of uncertain significance. J. Clin. Microbiol. 45(2), 313-316(2007).
32. Wahlstrom C, Iftner T, Dillner J, Dillner L. Population-based study of screening test performance indices of three human papillomavirus DNA tests. J. Med. Virol. 79(8), 1169-1175 (2007).
33. Smits HL, van-Gemen B, Schukkink R et al. Application of the NASBA nucleic acid amplification method for the detection of human papillomavirus type 16 E6-E7 transcripts. J. Virol. Methods 54(1), 75-81 (1995).
34. Sotlar K, Stubner A, Diemer D et al. Detection of high-risk human papillomavirus E6 and E7 oncogene transcripts in cervical scrapes by nested RT-polymerase chain reaction. J. Med. Virol. 74(1), 107-116 (2004).
35. Molden T, Kraus I, Skomedal H, Nordstrom T, Karlsen E PreTect HPV-Proofer: real-time detection and typing of E6/E7 mRNA from carcinogenic human papillomaviruses. J. Virol. Methods 142(1-2), 204-212 (2007).
36. Castle PE, Dockter J, Giachetti C et al. A cross-sectional study of a prototype carcinogenic human papillomavirus E6/E7 messenger RNA assay for detection of cervical precancer and cancer. Clin. Cancer Res. 13(9), 2599-2605 (2007).
37. Wang-Johanning F, Lu DW, Wang Y, Johnson MR, Johanning GL. Quantitation of human papillomavirus 16 E6 and E7 DNA and RNA in residual material from ThinPrep Papanicolaou tests using realtime polymerase chain reaction analysis. Cancer 94(8), 2199-2210 (2002).
38. Molden T, Kraus I, Karlsen F, Skomedal H, Nygard JF, Hagmar B. Comparison of human papillomavirus messenger RNA and DNA detection: a cross-sectional study of 4,136 women >30 years of age with a 2-year follow-up of high-grade squamous intraepithelial lesion. Cancer Epidemiol. Biomarkers Prev. 14(2), 367-372 (2005).
39. Molden T, Nygard JF, Kraus I et al. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: a 2-year follow-up of women with ASCUS or LSIL Pap smear. Int. J. Cancer 114(6), 973-976 (2005).
40. Molden T, Kraus I, Karlsen F, Skomedal H, Hagmar B. Human papillomavirus E6/E7 mRNA expression in women younger than 30 years of age. Gynecol. Oncol. 100(1), 95-100(2006).
41. Kraus I, Molden T, Erno LE, Skomedal H, Karlsen F, Hagmar B. Human papillomavirus oncogenic expression in the dysplastic portio; an investigation of biopsies from 190 cervical cones. Br. J. Cancer 90(7), 1407-1413 (2004).
42. Kraus I, Molden T, Holm R et al. Presence of E6 and E7 mRNA from human papillomavirus types 16, 18, 31, 33, and 45 in the majority of cervical carcinomas. J. Clin. Microbiol. 44(4), 1310-1317 (2006).
43. Cuschieri KS, Whitley MJ, Cubie HA. Human papillomavirus type specific DNA and RNA persistence - implications for cervical disease progression and monitoring. J. Med. Virol. 73(1), 65-70 (2004).
44. Sherman ME, Schiffman M, Cox JT. Effects of age and human papilloma viral load on colposcopy triage: data from the randomized Atypical Squamous Cells of Undetermined Significance/Low-Grade Squamous Intraepithelial Lesion Triage Study (ALTS). J. Natl Cancer Inst. 94(2), 102-107 (2002).
45. ASCUS-LSIL Traige Study (ALTS) Group. Results of a randomized trial on the management of cytology interpretations of atypical squamous cells of undetermined significance. Am. J. Obstet. Gynecol. 188(6), 1383-1392 (2003).
46. Cuzick J, Szarewski A, Cubie H et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 362(9399), 1871-1876(2003).
47. Naucler P, Ryd W, Tornberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N. Engl. J. Med. 357(16), 1589-1597(2007).
48. Bulkmans NW, Berkhof J, Rozendaal L et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 370(9601), 1764-1772 (2007).
49. Koliopoulos G, Arbyn M, Martin-Hirsch P, Kyrgiou M, Prendiville W, Paraskevaidis E. Diagnostic accuracy of human papillomavirus testing in primary cervical screening: a systematic review and metaanalysis of non-randomized studies. Gynecol. Oncol. 104(1), 232-246 (2007).
50. Davies P, Arbyn M, Dillner J et al. A report on the current status of European research on the use of human papillomavirus testing for primary cervical cancer screening. Int. J. Cancer 118(4), 791-796 (2006).
51. Naucler P, Ryd W, Tornberg S et al. HPV type-specific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br. J. Cancer 97(1), 129-132 (2007).
52. Nanda K, McCrory DC, Myers ER et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann. Intern. Med. 132(10), 810-819 (2000).
53. Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J. Liquid compared with conventional cervical cytology: a systematic review and meta-analysis. Obstet. Gynecol. 111(1), 167-177 (2008).
54. Meijer CJ, Snijders PJ, Castle PE. Clinical utility of HPV genotyping. Gynecol. Oncol. 103(1), 12-17(2006).
55. Bulkmans NW, Rozendaal L, Snijders PJ et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int. J. Cancer 110(1), 94-101 (2004).
56. Kitchener HC, Almonte M, Wheeler P et al. HPV testing in routine cervical screening: cross sectional data from the ARTISTIC trial. Br.J. Cancer 95(1), 56-61 (2006).
57. Jakobsson M, Gissler M, Sainio S, Paavonen J, Tapper AM. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet. Gynecol. 109(2 Pt 1), 309-313(2007).
58. Sjoborg KD, Vistad I, Myhr SS et al. Pregnancy outcome after cervical cone excision: a case-control study. Acta Obstet. Gynecol. Scand. 86(4), 423-428 (2007).
59. Nohr B, Tabor A, Frederiksen K, Kjaer SK. Loop electrosurgical excision of the cervix and the subsequent risk of preterm delivery. Acta Obstet. Gynecol. Scand. 86(5), 596-603 (2007).
60. Bruinsma F, Lumley J, Tan J, Quinn M. Precancerous changes in the cervix and risk of subsequent preterm birth. BJOG 114(1), 70-80 (2007).
61. Ratman S, Coutlee F, Bentley J et al. HPV E6/E7 mRNA testing in cervical cancer screening: preliminary results from a multicenter Canadian study. Presented at: 24th International Papillomavirus Conference. Beijing, China, November 3-9 (2007) (Abstract).
62. Trope A, Sjoborg KD, Eriksen T et al. Comparison of HPV DNA- and RNA-testing in women with cervical neoplasia. Presented at: 24th International Papillomavirus Conference. Beijing, China, November 3-9 (2007) (Abstract).
63. Smith JS, Lindsay L, Hoots B et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int. J. Cancer 121(3), 621-632 (2007).
64. Schiffman M, Khan MJ, Solomon D et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J. Natl Cancer Inst. 97(2), 147-150 (2005).
65. Andersson S, Hansson B, Norman I et al. Expression of E6/E7 mRNA from 'high risk human papillomavirus in relation to CIN grade, viral load and pl6INK4a. Int. J. Oncol. 29(3), 705-711 (2006).